Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma

Journal of Allergy and Clinical Immunology

Volumn 111, Issue 1, 2003, Pages 87-90

  Corren, Jonathan ^a   Casale, Thomas ^b   Deniz, Yamo ^c   Ashby, Mark ^c  

^a Allergy Research Foundation   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c GENENTECH INC   (United States)

Author keywords

Allergy; Asthma; Exacerbation; Hospitalization; Immunoglobulin E; Omalizumab

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN E; OMALIZUMAB;

ALLERGIC ASTHMA; ARTICLE; ASTHMA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; EMERGENCY TREATMENT; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

EID: 0037248058     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.49     Document Type: Article

References (15)

1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. NHBLI/WHO workshop report. National Institutes of Health, National Heart, Lung, and Blood Institute, January 1995. NIH publication number 95-3659.
2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med 1992;326:862-6.
3. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997;156:787-93.
4. Lemanske RF Jr, Busse WW. Asthma. JAMA 1997;278:1855-73.
5. Fick RB Jr. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulmon Med 1999;5:76-80.
6. Easthope S, Jarvis B. Omalizumab. Drugs 2001;61:253-60.
7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
8. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al. Treatment of childhood asthma with anti-IgE antibody (omalizumab). Pediatrics 2001;108:e36.
9. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, Thirlwell J, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
10. Efron B, Tibshirani RJ. An Introduction to the bootstrap. New York: Chapman & Hall: 1993.
11. Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002 Jul;20:73-8.
12. Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21:737-44.
13. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982-6.
14. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995;310:1225-9.
15. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002;324:1-5.